See What HealthDay Can Do For You
Contact Us

FDA Approves New Type of Antibiotic for Impetigo

Altabax is a new molecular entity approved for patients nine months of age or older

FRIDAY, April 13 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new molecular entity, Altabax (retapamulin ointment), for the treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients 9 months of age and older.

Altabax is a pleuromutilin, a class of drug that inhibits protein synthesis in bacteria by binding to the 50S sub-unit of ribosomes.

Manufactured by GlaxoSmithKline, the antibiotic is applied twice daily for a five-day period. Approval was based on clinical trials involving about 2,000 adults and children, who were compared to 1,000 patients treated with a placebo or other antibiotics.

The clinical success rate was 85.6 percent compared with 52.1 percent for placebo. About 1.4 percent of patients experienced skin irritation, which was the most common side effect.

"Altabax provides clinicians with a convenient new means to effectively fight the bacteria that cause impetigo through an effect that is different from other antibiotics," said Stan Block, M.D., president of Kentucky Pediatric and Adult Research Inc., in a statement issued by GlaxoSmithKline. "In vitro, this new topical antibiotic has shown a low potential for the development of resistance, possibly because it works in a unique manner compared to other antibiotics."

More Information - FDA
More Information - GlaxoSmithKline

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.